Jennifer B. Shannon

TOP-280 Long-term safety, tolerability and maintenance of efficacy of linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis

Christopher L. Bowlus, Stuart C Gordon, David O. Jones, Andreas E. Kremer et autres

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Gideon M. Hirschfield, Christopher L. Bowlus, David E.J. Jones, Andreas E. Kremer et autres

ca, us, gb, ch, jp, cn, mx, es (code pays fourni par la source)

O8 Linerixibat significantly improves cholestatic pruritus in primary biliary cholangitis (PBC): results of the pivotal phase 3 GLISTEN trial

Gideon Hirshfield, Christopher L. Bowlus, D. I. Jones, Andreas E. Kremer et autres

Introduction Cholestatic pruritus is common, debilitating and undertreated in patients with PBC. Here, we describe the results of GLISTEN (NCT04950127), a Phase 3 study investigating efficacy and safety of linerixibat (ileal bile acid transporter inhibitor) for pruritus in PBC. Methods In this …

ca, us, gb, ch, jp, it, cn, mx, es (code pays fourni par la source)

Linerixibat significantly improves cholestatic pruritus in primary biliary cholangitis: results of the pivotal Phase 3 GLISTEN trial

Gideon M. Hirschfield, Christopher L. Bowlus, D. I. Jones, Andreas E. Kremer et autres

Background and Aims: Cholestatic pruritus is common, debilitating and undertreated in patients with primary biliary cholangitis (PBC). Here, we describe the results of GLISTEN (NCT04950127), a Phase 3 study investigating the efficacy and safety of the ileal bile acid transporter inhibitor linerixibat …

ca, us, gb, ch, jp, it, cn, mx, fi (code pays fourni par la source)

GS-011 Linerixibat significantly improves cholestatic pruritus in primary biliary cholangitis: results of the pivotal phase 3 GLISTEN trial

Gideon M. Hirschfield, Christopher L. Bowlus, David Jones, Andreas E. Kremer et autres

Mo1623: EARLY PRESENTATION AND UNDERTREATMENT OF CHOLESTATIC PRURITUS IN PRIMARY BILIARY CHOLANGITIS (PBC): INSIGHTS FROM THE PHASE 3 GLISTEN TRIAL BASELINE DATA

Marlyn J. Mayo, Gideon M. Hirschfield, Christopher L. Bowlus, Dave E. Jones et autres

Insufficient control of cholestatic pruritus in primary biliary cholangitis (PBC) with current therapies: baseline data from the ongoing Phase 3 GLISTEN (Global Linerixibat Itch STudy of Efficacy and safety iN PBC) trial

Gideon M. Hirschfield, Christopher L. Bowlus, D. I. Jones, Andreas E. Kremer et autres

Background: Cholestatic pruritus is common in PBC, negatively impacts quality of life and efficacy of current therapies is limited. Linerixibat, an oral ileal bile acid transporter inhibitor, is currently in development for the treatment of pruritus in PBC. Here, we report baseline …

ca, us, gb, ch, jp, it, cn, mx (code pays fourni par la source)

Daprodustat and Heart Failure in CKD

Jonathan W. Cunningham, Brian Claggett, Renato D. Lópes, John J.V. McMurray et autres

Key Points Patients with CKD face meaningful risk of heart failure hospitalization. Daprodustat compared with darbepoetin was associated with a nonsignificantly greater number of heart failure hospitalizations in non-dialysis patients. Background Patients with CKD are at higher risk of heart failure. The …

us, gb, au (code pays fourni par la source)

Hemoglobin Stability in the ASCEND-TD Trial

Anjali Acharya, Anjay Rastogi, Vivekanand Jha, Ajay Singh et autres

Background: Daprodustat (Dapro), a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI), has been investigated as a treatment for anemia of chronic kidney disease (CKD) in the ASCEND program. Maintaining hemoglobin (Hb) levels in the target range per clinical guidelines for patients (pts) with CKD …

us, in (code pays fourni par la source)

#3807 HEART FAILURE IN ASCEND-ND AND ASCEND-D

Ajay Singh, Brian Claggett, Vlado Perkovic, Thomas F. Hiemstra et autres

Abstract Background and Aims Heart failure (HF) is a common cardiovascular (CV) complication in chronic kidney disease (CKD) [1]. Two CV outcome trials (ASCEND-ND [NCT02876835][2] and ASCEND-D [NCT02879305][3]) have provided the principal assessment of CV risk with daprodustat in CKD: both studies …

us, au (code pays fourni par la source)

#3715 THE EFFECT OF DAPRODUSTAT ON INTRAVENOUS IRON USE IN PATIENTS WITH CKD-RELATED ANAEMIA ON DIALYSIS IN THE ASCEND TRIALS

Pablo E. Pérgola, Tomas Ganz, Elizabeta Nemeth, Christine K. Bailey et autres

Abstract Background and Aims Intravenous (IV) iron is frequently needed in patients with chronic kidney disease (CKD) to ensure sufficient iron is available for erythropoiesis. However high doses of IV iron and erythropoiesis stimulating agents (ESAs) may be associated with risks in …

us, it (code pays fourni par la source)

#3704 EU REGION-SPECIFIC CARDIOVASCULAR EVENT DATA FOR DAPRODUSTAT IN ASCEND-D AND ASCEND-ND

David C. Wheeler, Aleix Cases, Christian Combe, Bart Maes et autres

Abstract Background and Aims Daprodustat (GSK1278863) is a hypoxia-inducible factor prolyl hydroxylase inhibitor under investigation for the treatment of anaemia of chronic kidney disease. Phase 3 studies in dialysis (ASCEND-D) and non-dialysis (ASCEND-ND) patients demonstrated the non-inferiority of daprodustat vs recombinant human …

gb, es, fr, be, it, de (code pays fourni par la source)